CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA)
Key claim: Standard-dose clopidogrel (75 mg/day) may provide inadequate platelet inhibition in ET patients due to accelerated platelet turnover and variable prodrug activation, and platelet function testing to identify poor responders who may benefit from dose escalation to 150 mg/day could improve thrombosis prevention.
Abstract
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm associated with increased platelet production and activation, leading to a high risk of thrombotic complications. Low-dose aspirin is the standard antiplatelet therapy for thrombosis prevention; however, the accelerated platelet turnover characteristic of ET results in rapid recovery of platelet function, making once-daily aspirin insufficient in many patients. Consequently, twice-daily low-dose aspirin is currently recommended to achieve adequate and sustained platelet inhibition.
For patients intolerant to aspirin, clopidogrel 75 mg/day is the approved alternative. Clopidogrel irreversibly inhibits the platelet P2Y12 receptor, but its pharmacodynamic effect is highly variable because it is a prodrug requiring metabolic activation. Studies in non-ET populations have shown that higher clopidogrel doses (150 mg/day) provide stronger and more consistent platelet inhibition without significantly increasing bleeding risk.
Evidence on clopidogrel use in ET is limited, but available data suggest that standard-dose therapy may result in inadequate platelet inhibition, potentially reducing antithrombotic efficacy. Platelet function testing can identify patients with high residual platelet reactivity (“poor responders”), who may benefit from dose escalation. Therefore, in ET patients requiring clopidogrel therapy, assessment of platelet responsiveness may help optimize treatment, ensuring adequate platelet inhibition and potentially improving protection against thrombotic events.
Why this matters
ET thrombosis prevention currently rests on low-dose aspirin, with limited subtype-specific data on alternative or adjunctive antiplatelet strategies. CRETA reframes clopidogrel pharmacology through an ET-specific lens — accelerated platelet turnover and variable prodrug activation — and proposes platelet-function-guided dose escalation, adding a mechanistic hypothesis to the ET antithrombotic landscape alongside the AVAJAK DOAC trial and genotype-stratified risk work.